Mega Contracts Monitor ($100M+) — August 12, 2026

The $113.9M firm-fixed-price delivery order for VA medical disability exams has $104.6M already outlaid, signaling near-complete revenue realization and low performance risk for Leidos in a legally mandated program.

The 16-year Medicare National Supplier Clearinghouse contract ends September 2024 with only $14.6M outlaid of $212.5M obligated, creating a catalyst event around renewal or re-compete that could unlock significant revenue or signal loss of incumbent position.

The 5-year firm-fixed-price BPA call for 11 border patrol station projects has a total potential value of $162.3M including options, offering Jacobs a steady $21.1M annual revenue stream aligned with sustained border security funding.

The 12-year, $259.8M total value contract for biodefense R&D carries no profit fee, meaning Roche's margin contribution is modest even as it secures stable government funding for medical countermeasure development.

Jacobs Engineering's $105.6M firm-fixed-price contract for 11 border patrol station projects carries high pricing risk; cost overruns on any project would directly impact margins given the fixed-price structure.

Palmetto GBA's $212.5M CMS contract has only $14.6M outlaid over 16 years, indicating potential under-execution or funding constraints; the September 2024 end date creates re-compete risk for the incumbent.

All four contracts are civilian (HHS, VA, DHS); only one of four is defense-related, exposing the portfolio to potential civilian budget cuts or continuing resolution impacts on non-defense discretionary spending.

The Leidos $113.9M VA contract was won under full and open competition with no set-aside, meaning the incumbent advantage is not protected; competitors could win future VA medical exam contracts in other regions.

Leidos Holdings' strong execution on the $113.9M VA contract (92% outlaid) positions it favorably for follow-on VA medical disability exam contracts in other regions, given the legally mandated demand under the Veterans Benefits Improvement Act.

Jacobs Engineering's $105.6M DHS/CBP contract could expand to the full $162.3M potential value through option exercises, driven by sustained border security policy priorities and immigration enforcement funding.

Roche's $183.8M BARDA contract for biodefense R&D could see scope expansion or follow-on awards with a fee structure if pandemic preparedness priorities increase under future NDAA or HHS budget cycles.

Three of four contracts ($509.9M total) are from HHS and VA, signaling sustained federal investment in healthcare administration (Medicare, VA disability exams) and biodefense R&D, with limited defense exposure in this digest.

Jacobs Engineering's $105.6M DHS/CBP contract for 11 border patrol stations across four states confirms ongoing investment in physical border infrastructure, aligned with current immigration enforcement priorities.

{"entity" => "Palmetto GBA", "reason" => "$212.5M CMS contract ending September 2024 with only $14.6M outlaid; renewal or re-compete decision is a major catalyst for revenue recognition or loss of incumbent position.", "trigger" => "September 2024 contract end date; CMS announcement of follow-on award or re-compete"}

{"entity" => "Leidos Holdings", "reason" => "Strong execution on $113.9M VA contract (92% outlaid) positions company for follow-on VA medical exam contracts in other regions.", "trigger" => "VA solicitation for medical disability exams in additional regions"}

{"entity" => "Jacobs Engineering Group", "reason" => "$105.6M DHS/CBP contract has option value up to $162.3M; execution risk on 11 fixed-price projects needs monitoring.", "trigger" => "Option exercise announcements; project milestone reports"}

{"entity" => "Hoffmann-La Roche", "reason" => "$183.8M BARDA contract is cost-no-fee, limiting profit; watch for scope expansion or follow-on contracts with fee structure.", "trigger" => "BARDA option exercise announcements; new biodefense R&D solicitations"}